ASCO Skin Cancer News: Lifileucel Boosts Five-year Survival Rates in Advanced Melanoma
Lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) improved overall survival (OS) results and durable responses at five years following one-time treatment, according to a Phase 2 C-144-01 clinical trial of advanced melanoma patients.